10 likes | 155 Views
HIV Prevention Options Timeline * **. AVAC, December 2012. Bangkok Tenofovir Study/CDC 4370. 2005. Oral TDF. TIMELINE LEGEND. Oral TDF. Partners PrEP. Partners PrEP (no placebo). 2008. Oral TDF/FTC. Positive efficacy result. TFV gel. VOICE/MTN 003. 2009. Arm stopped.
E N D
HIV Prevention Options Timeline *** AVAC, December 2012 Bangkok Tenofovir Study/CDC 4370 2005 Oral TDF TIMELINE LEGEND Oral TDF Partners PrEP Partners PrEP (no placebo) 2008 Oral TDF/FTC Positive efficacy result TFV gel VOICE/MTN 003 2009 Arm stopped Rectal TFV gel Regulatory submission/filing Oral TDF/FTC TDF2/CDC 4940 TDF2 Open-Label Extension DPV ring 2007 TMC278 LA Injectable iPrEx iPrEx Open-Label Extension (OLE) 2007 Planned FEM-PrEP DNA/Ad5 2009 Final results pending Additional demonstration projects & intermittent PrEP studies Pox-Protein US FDA approval CAPRISA 004 2007 TFV gel CAPRISA 008 VOICE/MTN 003 Earliest regulatory submission 2009 FACTS 001 Rectal TFV gel FACTS 002 and other adolescent studies DPV Ring MTN 017 Earliest regulatory submission ASPIRE/MTN 020 TMC 278 LA Inject. The Ring Study/IPM 027 Possible TMC278 LA Injectable DNA/Ad5 HVTN 505 2009 South Africa Licensure RV 144 2004 Pox-Protein South Africa Research Various Phase I/II preliminary and bridging studies Thai Licensure * Trial end-dates are estimates; due to the nature of clinical trials the actual dates may change. For full trial details, see www.avac.org/pxrd. ** Not all trials included are effectiveness trials. Trials included on this list are mainly phase II/IIb, III/IIIb and IV trials.